Pfizer Inc. (NYSE:PFE) Shares Acquired by WealthShield Partners LLC

WealthShield Partners LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.4% during the first quarter, Holdings Channel reports. The fund owned 24,403 shares of the biopharmaceutical company’s stock after purchasing an additional 1,459 shares during the quarter. WealthShield Partners LLC’s holdings in Pfizer were worth $618,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Exencial Wealth Advisors LLC boosted its stake in shares of Pfizer by 1.7% during the first quarter. Exencial Wealth Advisors LLC now owns 76,716 shares of the biopharmaceutical company’s stock valued at $1,944,000 after acquiring an additional 1,254 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after acquiring an additional 9,041,990 shares during the last quarter. Palacios Wealth Management LLC boosted its stake in shares of Pfizer by 1,096.3% during the first quarter. Palacios Wealth Management LLC now owns 256,891 shares of the biopharmaceutical company’s stock valued at $6,510,000 after acquiring an additional 235,417 shares during the last quarter. Finally, PrairieView Partners LLC boosted its stake in Pfizer by 47.5% in the 1st quarter. PrairieView Partners LLC now owns 3,159 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 1,018 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Leerink Partners decreased their price target on Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research note on Wednesday, April 30th. Bank of America raised their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday. BMO Capital Markets decreased their price target on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Finally, The Goldman Sachs Group raised their price target on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $28.44.

Pfizer Stock Performance

NYSE PFE opened at $23.95 on Thursday. The firm has a market capitalization of $136.15 billion, a P/E ratio of 12.74, a P/E/G ratio of 0.90 and a beta of 0.52. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The business’s 50-day simple moving average is $24.40 and its 200-day simple moving average is $24.53.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.33% and a net margin of 16.84%. Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer’s payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.